• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Role of GLP-1 receptor agonist in diabetic cardio-renal disorder: Recent updates of clinical and pre-clinical evidence
Curr Diabetes Rev. 2023 Aug 9. doi: 10.2174/1573399820666230809152148. Online ahead of print.ABSTRACTCardiovascular complications and renal disease is the growing cause of mortality in patients with diabetes. The subversive complications of diabetes such as hyperglycemia, hyperlipidemia and insulin resistance lead to an increase in the risk of myocardial infarction (MI), stroke, heart failure (HF) as well as chronic kidney disease (CKD). Among the commercially available anti-hyperglycemic agents, incretin-based medications appear to be safe and effective in the treatment of type 2 diabetes mellitus (T2DM) and associated ca...
Source: Current Diabetes Reviews - August 10, 2023 Category: Endocrinology Authors: Sanket Seksaria Bhaskar Jyoti Dutta Mandeep Kaur Ghanshyam Das Gupta Surendra H Bodakhe Amrita Singh Source Type: research

Dulaglutide and Cardiovascular and Heart Failure Outcomes in Patients With and Without Heart Failure: A Post ‐hoc Analysis from the REWIND Randomized Trial
ConclusionsDulaglutide was not associated with a reduction in HF events in patients with type 2 diabetes regardless of baseline HF status over 5.4  years of follow up.This article is protected by copyright. All rights reserved.
Source: European Journal of Heart Failure - September 8, 2022 Category: Cardiology Authors: Kelley R. H. Branch, Gilles R. Dagenais, Alvaro Avezum, Jan Basile, Ignacio Conget, William C. Cushman, Petr Jansky, Mark Lakshmanan, Fernando Lanas, Lawrence A. Leiter, Prem Pais, Nana Pogosova, Peter J. Raubenheimer, Lars Ryden, Jonathan E Tags: Research Article Source Type: research

Update on Cardiovascular Safety of Incretin-Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials
ConclusionsThis meta-analysis demonstrated that GLP-1RAs were associated with a significant reduction in major adverse CV events, CV death, stroke and death from any cause, while DPP-4 inhibitors were comparable to placebo for all CV outcomes, including hospitalizations for heart failure.RésuméObjectifsLes auteurs de deux grands essais randomisés ont récemment publié leurs conclusions concernant les effets d'un agoniste du récepteur au glucagon-like peptide-1 (A-GLP-1R) (essai HARMONY) et d'un inhibiteur de la dipeptidyl peptidase 4 (DPP-4) (essai CARMELINA) sur les bénéfices cardiovasculaires (CV) chez les patie...
Source: Canadian Journal of Diabetes - June 5, 2019 Category: Endocrinology Source Type: research

Update in Cardiovascular Safety of Incretin-Based Therapy in Adults with Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials
ConclusionThis meta-analysis demonstrated that GLP-1RAs were associated with a significant reduction in MACE, CV death, stroke, and death from any cause, while DPP-4 inhibitors were comparable to placebo for all CV outcomes, including hospitalizations for HF.
Source: Canadian Journal of Diabetes - April 14, 2019 Category: Endocrinology Source Type: research

Combination of SGLT-2 inhibitors and GLP-1 receptor agonists: potential benefits in surrogate and hard endpoints.
CONCLUSION: The combination of metformin with SGLT2i, GLP-1 RA, and a potent statin, in high CVD risk patients with DM, is expected to substantially reduce CVD mortality and morbidity, improving the quality of life of patients with DM at the same time. Prospective studies are needed to confirm this finding. PMID: 29865997 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - June 3, 2018 Category: Drugs & Pharmacology Authors: Doumas M, Imprialos Κ, Stavropoulos K, Reklou A, Sachinidis A, Athyros VG Tags: Curr Pharm Des Source Type: research

The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis.
CONCLUSIONS: Incretin-based therapies show similar cardiovascular risk in comparison with metformin, insulin, thiazolidinediones, alpha-glucosidase inhibitor and sodium-glucose co-transporter 2. GLP-1RA could decrease the risk compared with sulfonylurea or placebo, while DPP-4I appears to have neutral effect on cardiovascular risk. PMID: 29320889 [PubMed - as supplied by publisher]
Source: Expert Opinion on Drug Safety - January 13, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research

Design and Baseline Characteristics of Participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) Trial of Dulaglutide's Cardiovascular Effects
ConclusionThe REWIND trial's international scope, high proportion of women, high proportion of people without prior cardiovascular disease, and inclusion of participants whose mean baseline HbA1c was 7.3% suggests that its cardiovascular and safety findings will be directly relevant to the typical middle‐aged patient seen in general practice throughout the world.
Source: Diabetes, Obesity and Metabolism - June 1, 2017 Category: Endocrinology Authors: Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Matthew C Riddle, Lars Ryd én, Denis Xavier, Charles Messan Atisso, Alvaro Avezum, Jan Basile, Namsik Chung, Ignacio Conget, William Tags: ORIGINAL ARTICLE Source Type: research

Novel antidiabetic drugs and cardiovascular risk: primum non nocere
Conclusions Results of safety outcome studies focused on CV events, including HF and mortality for CV causes, are not homogeneous. A critical analysis of these studies may help cardiologists and diabetes specialists to adapt their therapeutic choices to individual patients.
Source: Nutrition, Metabolism and Cardiovascular Diseases - June 15, 2016 Category: Nutrition Source Type: research

Cardiovascular Effects of Incretin-Based Therapies.
This article reviews the most recent CV outcome trials of the DPP-4 inhibitors (SAVOR-TIMI 53, EXAMINE, and TECOS) as evidence that the incretin-based therapies have acceptable CV safety profiles for patients with T2DM. The studies differ with regard to patient population, trial duration, and heart failure outcomes but show similar findings for CV death, nonfatal myocardial infarction, and stroke, as well as hospitalization for unstable angina. PMID: 26768240 [PubMed - in process]
Source: Annual Review of Medicine - January 14, 2016 Category: Journals (General) Authors: White WB, Baker WL Tags: Annu Rev Med Source Type: research

Diabetes, incretin hormones and cardioprotection
The diabetes pandemic In 2012 an estimated 371 million people had diabetes and of those about a half were undiagnosed. That number is set to expand to 552 million by 2030. Type 2 diabetes mellitus (T2DM) constitutes 85–95% of all diabetes in high income nations and may account for an even greater proportion in their low and middle income counterparts (figure 1). As a global pandemic, diabetes claimed the lives of 4.8 million people in 2012, half of whom were below the age of 60 years.w1 The predominant cause of morbidity and mortality in diabetes is cardiovascular disease, with at least a twofold excess risk of ...
Source: Heart - September 9, 2014 Category: Cardiology Authors: Myat, A., Redwood, S. R., Gersh, B. J., Yellon, D. M., Marber, M. S. Tags: Diabetic heart disease, Education in Heart, Drugs: cardiovascular system, Epidemiology, Diabetes, Metabolic disorders Source Type: research